Meet the Leaders

Biological Modeling Specialty Section

James V. Bruckner, Ph.D., Vice President

Dr. Bruckner received his Ph.D. from the University of Michigan. He has held faculty positions are the University of Kansas, the University of Texas Medical School at Houston, and is currently at the University of Georgia (UGA). He was director of UGA’s Graduate Program in Toxicology for 15 years. Dr. Bruckner has served on editorial boards of Toxicology and Applied Pharmacology, Journal of Toxicology and Environmental Health, Toxicology, Chemosphere and International Journal of Toxicology. He is lead author of a chapter entitled “Toxic Effects of Solvents and Vapors” in Casarette and Doull’s Toxicology: The Basic Science of Poisons. His research focus is on the toxicology and toxicokinetics of volatile organic chemicals (VOCs), drug interactions at environmental exposure levels, and toxicokinetic bases for susceptibility of children to insecticides. Dr. Bruckner has served on a variety of expert panels and committees for the U.S. EPA, NIEHS, NASA, Air Force, ATSDR/CDC, FDA and the National Academy of Sciences.

Biological Modeling Specialty Section

Richard A. Corley, Ph.D., Past President

Dr. Corley is currently a Laboratory Fellow in the Biological Monitoring & Modeling Group, Pacific Northwest National Laboratory (PNNL), Richland, WA. He received his Ph.D. in Environmental Toxicology from the University of Illinois in 1985 before joining The Dow Chemical Company’s Toxicology Research Laboratory; initially as a Postdoctoral Fellow in physiologically based pharmacokinetic (PBPK) modeling, and later as a scientist and group leader of the chronic toxicology and inhalation toxicology research groups. Since joining PNNL in 1996, Dr. Corley has worked to establish a multi-disciplinary research program in pharmacokinetic modeling, 3D imaging, and multi-scale computational toxicology. In that capacity, he continues to serve as a principle investigator or collaborator in government- and industry-sponsored studies to develop, validate, and apply PBPK models and 3D/computational fluid dynamics models of the respiratory system to reduce the uncertainties in target tissue dosimetry for human health risk assessments and improvements in therapeutic interventions. He has served on several committees, working groups, or advisory panels for the NAS, EPA, ILSI, ATSDR, OTA, and CIIT, the editorial board of Toxicol. Appl. Pharmacol., and as an ad hoc reviewer for NIH. He is currently an officer of the Biological Modeling Specialty Section and a member of the Pacific Northwest Association of Toxicologists (PANWAT); he has also served as a past member of SOT’s Program Committee.

Biotechnology Specialty Section

Barbara Mounho, Ph.D., D.A.B.T., President

Barbara joined the toxicology department at Amgen Inc. (Thousand Oaks, CA) in 2002. Her work involves supporting the development of biopharmaceutical candidates for various therapeutic areas such as oncology and inflammation. She has expertise in the preclinical safety assessment of protein therapeutics including monoclonal antibodies, recombinant and fusion proteins, and antibody-drug conjugates. Barbara recently transitioned to Amgen’s Regulatory Biosimilar Group, and is involved in advancing advocacy efforts to establish a science-based pathway for U.S. biosimilars.

Prior to joining Amgen Inc., she was a toxicologist in the Safety Assessment Department at Genentech Inc. (South San Francisco, CA), and worked on the development of various drug candidates including small and large molecule drug products. Barbara is a diplomate of the American Board of Toxicology, and currently a member of various organizations including the American College of Toxicology (ACT), Society of Toxicology (SOT) and BioSafe. Barbara is actively involved in the toxicology field, and has served as a member of the ACT Council (2005–2008), the ACT Continuing Education Committee (2003–2005), and has served as the chair for the ACT Study Director Training Continuing Education Course for several years. She has also served as a member of the SOT Continuing Education Committee (2006–2009), the Continuing Education Committee Student Liaison (2008), and is currently the President of the SOT Biotechnology Specialty Section. She has authored several journal articles and book chapters, as well as presented at numerous meetings and conferences on challenges associated with the preclinical development of biotherapeutics.

Biotechnology Specialty Section

Hanan Ghantous, Ph.D., DABT, Vice President-Elect

Dr. Ghantous received a B.Sc. in Pharmacy from the University of Baghdad, Iraq, a M.Sc. in Pharmacology from the University of Strathclyde, Scotland and a Ph.D. in Toxicology from the University of Uppsala, Sweden. She was a postdoctoral fellow in the Department of Anesthesiology, Pharmacology/Toxicology Division, University of Arizona, and received her board certification as a Diplomate of the American Board of Toxicology (DABT) in 1995. In 2001 Dr. Ghantous joined the U.S. Food and Drug Administration, and since 2007 she has been the Pharmacology/Toxicology supervisor at the Division of Antiviral Products, Center for Drug Evaluation and Research. Since joining the U.S. FDA, she has evaluated pharmacology/toxicology data to support the safe clinical development of small molecule drugs and biological products. Dr. Ghantous has presented at national and international scientific and regulatory meetings, has served on several U.S. FDA committees, has been involved in writing Guidance documents and has represented the Agency at various public forums. Before U.S. FDA, Dr. Ghantous worked for approximately 10 years at the DuPont Company, as a Research Toxicologist at DuPont Haskell Laboratory, and Project Registration Manager—U.S. Regulatory Toxicologist at the Crop Protection Division. She has been a member of the Society of Toxicology since 1989 and the American College of Toxicology since 2000. She is serving as a member of the Continuing Education Committee of SOT (2010–2013), and as a councilor in the Biotechnology Specialty Section. She is also serving as a member of the Board of Directors of the American Board of Toxicology (2010–2014). Dr. Ghantous has over 20 years of combined experience in general and regulatory

Carcinogenesis Specialty Section

Vernon E. Walker, D.V.M., Ph.D., President

Dr. Walker received his D.V.M. from The University of Tennessee in 1983 and a Ph.D. from Duke University in 1991. He was a pathology resident at the University of Alabama at Birmingham and Auburn University (1983–1985) and a postdoctoral fellow in pathology at the University of North Carolina (1991–1993). In 2009, Dr. Walker joined the Department of Pathology, University of Vermont. He has served as an ad hoc reviewer for the NIH, U.S. FDA, and NIOSH, and reviewed grants for the American Chemistry Council and the Health Effects Institute (1994–Present). He has served on numerous advisory committees for U.S. and Canadian agencies, foundations, and industry. He has been a member of the SOT since 1997, served as a councilor in the Carcinogenesis Specialty Section (2008–Present), and has been active in the student awards program of that specialty section. His research interests are in chemical carcinogenesis, in particular low-dose effects of mutagens.

Carcinogenesis Specialty Section

David E. Williams, Ph.D., Vice President

Dr. Williams (Professor, Environmental and Molecular Toxicology, Senior Scientist, The Linus Pauling Institute, member Environmental Health Sciences Center and Director, Superfund Research Program at Oregon State University) received his B.S. from Reed College and Ph.D.in Biochemistry and Biophysics at Oregon State University (OSU). Following postdoctoral training in Biochemistry at The Medical College of Wisconsin, Dr. Williams returned to OSU and has been on the faculty for 23 years. Dr. Williams’ research area is drug metabolism, carcinogenesis and cancer chemoprevention. He serves as an Associate Editor for TAAP. In addition to the Carcinogenesis Specialty Section, he has served on the following SOT committees: Program (1991–1994); Education (1997–1999); K–12 Education (1997–1998, Chair,1998–1999); Food Safety Specialty Section (Secretary/Treasurer, 1998–2000); and PANWAT (Secretary/Treasurer, 1990–1992; President, 1996–1997). He was a member of AL-TX1 (chair, 2 years) and is currently serving on XNDA. He has authored 165 manuscripts and is the 2009 OSU Alumni Distinguished Professor.

Cardiovascular Specialty Section

Timothy R. Nurkiewicz, Ph.D., President

Dr. Nurkiewicz earned his B.S. from Pennsylvania State University and his M.S. from West Virginia University (WVU). After serving in cardio-pulmonary rehabilitation at Allegheny General Hospital, he returned to WVU and earned his Ph.D. in 1999. Dr. Nurkiewicz performed his post-doctoral training at Texas A&M University in the Department of Medical Physiology. While trained as a microvascular physiologist, he has a broad background ranging from bench top in vitro experiments to clinical interactions. Currently, Dr. Nurkiewicz is an associate professor in the Department of Physiology and Pharmacology at the WVU School of Medicine, where he is also a member of the Center for Cardiovascular and Respiratory Sciences. He serves on the Editorial Board of several toxicology journals; is an ad hoc reviewer for numerous journals and study sections; and participates in various committees and consortiums at University, State and National levels. Dr. Nurkiewicz is a founding member of the Cardiovascular Toxicology Specialty Section.

Cardiovascular Specialty Section

Matthew Campen, Ph.D., M.S.P.H., Vice President

Dr. Campen received his B.S. from Virginia Polytechnic Institute in 1994, and his M.S.P.H. and Ph.D. from the University of North Carolina at Chapel Hill in 1997 and 2000, respectively. He completed his postdoctoral training at Johns Hopkins University, where he focused on Cardiopulmonary Physiology, in 2002. Over the next seven years, Dr. Campen worked concurrently as an Adjunct Assistant Professor at the University of New Mexico and an Associate Research Scientist (2002–2004) and Associate Scientist (2004–2009) at Lovelace Respiratory Research Institute. In 2007, he also took on the role of Director of Cardiovascular and Pulmonary Physiology, Toxicology Division, at Lovelace Respiratory Research Institute. Since 2009, Dr. Campen has served as an Associate Professor in the Department of Pharmaceutical Sciences, College of Pharmacy, at the University of New Mexico. He is a full member of the Society of Toxicology and is active in the Mountain West Regional Chapter and Inhalation and Respiratory Specialty Section, in addition to serving as Vice President and founding member of the Cardiovascular Toxicology Specialty Section.

Cardiovascular Specialty Section

Kevin Dreher, Ph.D., Vice President-Elect

Dr. Kevin Dreher received his B.S. in Chemistry from Villanova University in 1974 and his M.S. and Ph.D. degrees in Biochemistry from the Pennsylvania State University in 1977 and 1980, respectively. He was a postdoctoral staff fellow at the NIAID\NIH from 1980–1983 and Assistant Professor, Dept. of Biochemistry, West Virginia University School of Medicine from 1983–1987. Dr. Dreher is a senior investigator at the National Health and Environmental Effects Research Laboratory (NHEERL), U.S. EPA, Science Lead for NHEERL’s engineered nanoparticle health effects research program and Adjunct Professor at the North Carolina State University. Dr. Dreher has received numerous U.S. EPA Science and Technology Awards including the Agency’s Gold and Silver medals for his research. He has served, and continues to serve, on several NIEHS\NIH specialty grant peer-reviews, journal editorial boards, and national/international Science Advisory Boards. Dr. Dreher has been a member of SOT since 1995, served as Councilor for the Inhalation Specialty Section and is currently Vice-President Elect for the Cardiovascular Toxicology Specialty Section. Dr. Dreher’s research examines the pulmonary and cardiovascular effects of air pollutants and engineered nanomaterials. This research includes identifying host susceptibility\sensitivity factors and the development of predictive alternative testing methods.

Comparative and Veterinary Specialty Section

Kathleen L. Gabrielson, D.V.M., Ph.D., President

Dr. Gabrielson received her Ph.D. in Toxicology from the Johns Hopkins University Bloomberg School of Public Health, and she joined the department of Molecular and Comparative Pathobiology faculty in 2000. She has joint appointments in Environmental Health Sciences, Pathology, Pathobiology and CAAT. She has a supportive faculty role in the Bloomberg School of Public Health NIEHS center and the School of Medicine small animal imaging research program (SAIRP) for histopathology, in vivo imaging and animal model expertise. She serves on the editorial boards of Toxicologic Pathology and Cardiovascular Toxicology. Dr. Gabrielson has a teaching and clinical role in the MCP Comparative Veterinary Medicine postdoctoral training program. She currently serves as an officer for the American College of Veterinary Pathologists and the Society of Toxicology. She is a member of the SOT Continuing Education and K–12 committees and a proctor on the National Exam Committee of the American College of Veterinary Pathologists. She is the author or co-author of more than 60 peer-reviewed papers.

Comparative and Veterinary Specialty Section

Ann F. Hubbs, D.V.M., Ph.D., DACVP, Vice President

Dr. Hubbs received her D.V.M. from Texas A&M University, an M.S. from Purdue, and a Ph.D. from Colorado State University. She received a certificate of residency in veterinary pathology from Colorado State University, is board eligible in laboratory animal medicine, and is a Diplomate of the American College of Veterinary Pathologists. She has been at the National Institute for Occupational Safety and Health within CDC since 1992. Dr. Hubbs is also an adjunct associate professor at West Virginia University. She has authored or co-authored more than a hundred peer-reviewed publications, which have received numerous awards. Dr. Hubbs is a co-recipient of both the 2008 Bullard-Sherwood Award for Research to Practice and the 2008 National Occupational Research Agenda Partnering Award for Worker Health and Safety. She has received multiple awards for using her scientific skills in responding to important events, such as the anthrax events of 2001, Hurricane Katrina, and monkeypox.

Comparative and Veterinary Specialty Section

Louise Abbott, D.V.M., Ph.D., Vice President-Elect

Dr. Abbott received her B.A. in Biology from Whitman College, Ph.D. in Zoology from the University of Washington and D.V.M. from Washington State University. She has been a faculty member at Texas A&M University (TAMU) since 1993 and holds the rank of Associate Professor. Dr. Abbott has been a member of the TAMU Faculty of Toxicology since she joined the TAMU faculty. She uses mouse and zebrafish animal models to investigate mechanisms underlying the adverse effects of chronic, low dose methylmercury exposure on brain development and function. She has trained 15 graduate stidemts, with two M.S. students and three Ph.D. students trained through the TAMU Toxicology program, with an emphasis on neurotoxicology. Dr. Abbott currently teaches an undergraduate class in developmental neurotoxicology. She teaches histology and embryology to first year veterinary students and embryology and neuroscience to graduate students. She regularly reviews manuscripts for five toxicology journals and she serves on the editorial board for Toxicology Letters and the advisory board for the Journal of Applied Toxicology.

Comparative and Veterinary Specialty Section

Mike Murphy, D.V.M., Ph.D., J.D., DABT, DABVT, RAC, Past President

Dr. Murphy received his science education at Texas A&M University and legal training at William Mitchell College of Law. He is a Professor Emeritus of the University of Minnesota, where he published numerous senior authored manuscripts, book chapters, a text book, and gave hundreds of presentations. He also taught toxicology and regulatory affairs to graduate and veterinary students. Dr. Murphy has been a reviewer for federal and foundation grants, an ad hoc reviewer for numerous journals, and a consultant to companies providing expert reports or witness services. He has been a member of SOT since 1990 and has served as an officer in the Northland Regional Chapter and the Comparative and Veterinary Specialty Section. Dr. Murphy currently works for the U.S. FDA in the D.C. area.

Dermal Toxicology Specialty Section

Carol Sabourin, Ph.D., Vice President

Dr. Sabourin is Senior Research Leader in National Security Global Business at Battelle and Chief Scientist for the Biomedical Science and Technology product line. She received her M.S. in Biochemistry from Michigan State University in 1977 and her Ph.D. in Biology from the University of New Mexico in 1991. She has more than 25 years of professional experience in molecular biology, biochemistry, and molecular toxicology, and 11 plus years in biodefense research for both chemical and biological agents. Her research has focused on host immune response and biomarkers for chemical and biological agents. She currently serves as principal investigator for studies to identify immunological correlates of protection for biodefense vaccines. She is on the Editorial Board of the Journal of Biochemical and Molecular Toxicology and an ad hoc review for numerous journals. She is Adjunct Associate Professor in the Department of Pharmacology and Toxicology, School of Medicine at Wright State University where she teaches and has graduate students. She serves on the Materials Technical Advisory Committee for the U.S. Department of Commerce Bureau of Industry and Security. Dr. Sabourin has authored or co-authored more than 60 manuscripts, and numerous abstracts, presentations, and reports. She is currently an officer of the Dermal Toxicology Specialty Section.

Drug Discovery Toxicology Specialty Section

Craig E. Thomas, Ph.D., Vice President

Dr. Thomas is a Sr. Research Advisor in the Department of Investigative Toxicology at Lilly Research Laboratories. He joined Eli Lilly & Co. in 1996, and in 2000, he became the Department Head of Investigative Toxicology and Toxicology Projects at the Lilly Development Centre in Belgium. In 2005, he took over leadership of Lilly’s toxicogenomics efforts. Dr. Thomas became a full member of SOT and the Mechanisms Specialty Section in 1997, and is currently a member of the Drug Discovery Toxicology Specialty Section and the Ohio Valley Regional Chapter. He is a past recipient of the Mechanisms Specialty Section Carl C. Smith Award and has twice served as a judge on the committee. Dr. Thomas serves on the Advisory Council for the Critical Path Institute Predictive Safety Testing Consortium and has authored 45 peer reviewed journal articles and 25 invited review articles. He holds 4 U.S. patents and is the Co-Editor of the book “Oxygen Radicals and the Disease Process.”

Drug Discovery Toxicology Specialty Section

John W. Davis, II, Ph.D., Past President

John Davis is presently the director of investigative toxicology at Pfizer, St. Louis, leading a group of scientists in Drug Safety Research and Development responsible for preclinical toxicology screening and mechanistic studies; he has served as the toxicologist on numerous multidisciplinary project teams in both research as well as development; and he served on and led several clinical and preclinical toxicology issue management teams. Prior to joining Pfizer, John was a principal scientist in the Molecular Toxicology Group at Schering-Plough.

Dr. David received a B.S. in pharmacology and toxicology from the University of Wisconsin in 1990 and a Ph.D. in Molecular Toxicology from the Purdue University in 1998. He performed postdoctoral research on the regulation of kinase signaling and gene expression in normal human mammary epithelial cells at the University of New Mexico (mentor Scott Burchiel). John has authored 20 peer-reviewed publications and reviews and has given numerous invited seminars at both scientific meetings as well as academic institutions. He has also co-chaired multiple continuing education courses, symposia, and workshops at both SOT and ACT Annual Meetings including the most recent SOT meeting in which he co-chaired “Strategies to Integrate Systems Biology into In Vitro Screening in Early Nonclinical Safety Assessment.” John is a founding/charter member of the Drug Discovery Toxicology Specialty Session. He has also participated in multiple industry-wide consortiums including the nephrotoxicity working group of the ILSI-HESI toxicogenomics group and the Critical Path Initiative’s nephrotoxicity biomarkers working group. John is an Adjunct Clinical Full Professor in the College of Pharmacy at the University of New Mexico.

Ethical, Legal, and Social Issues Specialty Section

Phil Wexler, B.S., M.L.S., President

Mr. Wexler is a Technical Information Specialist at the National Library of Medicine’s Toxicology and Environmental Health Information Program, where he has been instrumental in developing and enhancing the TOXNET system. He oversees the NLM-SOT project, ToxLearn, spearheaded the development of the World Library of Toxicology, Chemical Safety and Environmental Health, and is a frequent teacher and lecturer on toxicology information systems.

Mr. Wexler is Editor-in-Chief of Elsevier’s Information Resources in Toxicology and the Encyclopedia of Toxicology, and the author of numerous papers. He is currently preparing the Taylor and Francis monograph, Chemicals, Environment, Health: A Global Management Perspective.

A past Chair of the SOT’s World Wide Web Advisory Committee, Mr. Wexler is also a member of the Education and Communications Work Group of the CDC/ATSDR’s National Conversation on Public Health and Chemical Exposure project, and the 2010 recipient of SOT’s Public Communications Award.

Ethical, Legal, and Social Issues Specialty Section

Melinda Pomeroy-Black, Past President

Melinda Pomeroy-Black is as currently an Assistant Professor of Biology at LaGrange College (LaGrange, GA), a private liberal arts college with approximately 1000 undergraduate students. She received her B.A. in Biology from Rhodes College and an MS in Pathology and PhD in Toxicology, both from Virginia Tech. She has been a member of SOT since 2002, serving on the Student Advisory Committee and as the graduate student representative to the National Capital Area Regional Chapter of SOT. Melinda has introduced several courses to the Biology major at LaGrange College, including Toxicology, Immunology and Histology. She is currently teaching a Senior Seminar course in Bioethics. Her research interests include neurotoxicology and alternative species in toxicology research.

Food Safety Specialty Section

James C. Griffiths, Ph.D., Vice President-Elect

James C. Griffiths, Ph.D. is Vice President of Food, Dietary Supplement, and Excipient Standards at the US Pharmacopeia, in charge of excipient, dietary supplement and food ingredient issues and publications. Prior to joining USP, Dr. Griffiths was the Senior Toxicologist and Director of Toxicology and Business Development in the toxicology consulting firm of the Burdock Group, located in Vero Beach, Florida. Dr. Griffiths has a doctoral degree in Toxicology from Rutgers University and the University of Medicine and Dentistry of New Jersey, and postdoctoral work in physiological chemistry from the Heinrich Heine University in Düsseldorf, Germany. He has over 25 years of regulatory and safety experience, with the U.S. FDA Center for Food Safety and Applied Nutrition, national trade associations (Distilled Spirits Council of the U.S. and the Flavor and Extract Manufacturers Association), and end-use consumer companies with pharmaceutical excipient, food additive, flavor, cosmetic, and personal care product lines (International Specialty Products and Avon Products). He is an adjunct professor with J.S.S. University Medical Campuses in Mysore and Ootacamund, India and on the editorial board of the Journal of Excipients and Food Chemicals. Dr. Griffiths is a Diplomate of the American Board of Toxicology, a Fellow of the Society of Biology, board certified in medical technology, and a member of the Society of Toxicological Pathology, Society of Regulatory Toxicology and Pharmacology, the American College of Toxicology, and the Institute of Food Technologists. Dr. Griffiths has been a member of Society of Toxicology since 1980 and is very active in the Food Safety Specialty Section (FS3), having served as both Secretary-Treasurer (1995–1997) and Councilor (2008–2010).

Immunotoxicology Specialty Section

Leigh Ann Burns-Naas, Ph.D., DABT, President

Dr. Burns-Naas received her Ph.D. from the Medical College of Virginia, completed an NIH postdoctoral fellowship at the Mayo Clinic, and is certified by the American Board of Toxicology. Her career has focused primarily on the strategic aspects and design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics. Dr. Burns-Naas maintains an active involvement in Immunotoxicology, including journal editorial board/ad hoc reviewer, teaching at local universities, participation in the HESI ITC, and membership on the Pfizer DSRD Immunotoxicology Council and Biotherapeutics and Biotechnology Network. In addition to her responsibilities with the Immunotoxicology Specialty Section, she is a Councilor for the Women in Toxicology Special Interest Group, founding member of the Biotechnology Specialty Section, former member of the Continuing Education Committee, and current member of the Scientific Program Committee. She is also a Past President of the American College of Toxicology.

Immunotoxicology Specialty Section

Rodney Dietert, Ph.D., Vice President

Dr. Dietert is Professor of Immunotoxicology in the Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY. He also serves as a consultant in developmental immunotoxicology for Burleson Research Technologies (BRT-Labs). While at Cornell, Dietert has held the posts of Director of the Institute for Comparative and Environmental Toxicology (ICET), Director of Graduate Studies for the Graduate Field of Immunology, Senior Fellow in the Cornell Center for the Environment and Director of the Cornell Program on Breast Cancer and Environmental Risk Factors (BCERF). Dietert’s research has produced more than 290 publications including over 170 research papers appearing in more than 60 scientific journals. His work was featured on the January 2009 cover of Chemical Research in Toxicology. Most recently, Dietert senior authored the general audience book, Strategies for Protecting Your Child’s Immune System (World Scientific) and edited the text, Immunotoxicity Testing: Methods and Protocols (Springer).

Immunotoxicology Specialty Section

Gregory S. Ladics, Ph.D., DABT, Vice President-Elect

Dr. Ladics received his B.S. cum laude from the Philadelphia College of Pharmacy and Science in 1987. In 1991, he received his Ph.D. from the Medical College of Virginia/Virginia Commonwealth University. He has been employed by the DuPont Co. for over 18 years, where he is presently a Senior Research Scientist. He has been a member of Society of Toxicology and the Immunotoxicology Specialty Section since 1989. In 1999, Dr. Ladics became a Diplomate of the American Board of Toxicology. He serves on the International Life Sciences Institute’s (ILSI) Technical Committee on Protein Allergenicity (Chair), and the ILSI Immunotoxicology Technical Committee. Dr. Ladics also chairs the Crop Life International Expert Allergy Team. He is a member of the Editorial Boards of the Journal of Immunotoxicology and Toxicology Letters. He has previously served as Councilor and on the Program Committee for the Immunotoxicology Specialty Section and received the Young Investigator Award in 2006 for accomplishments in the field of Immunotoxicology. Dr. Ladics has co-authored over 140 abstract, journal, and book chapter publications in the field of Immunotoxicology and Allergy.

Immunotoxicology Specialty Section

Jean Regal, Ph.D., Past President

Dr. Regal is currently a Professor in the University of Minnesota Medical School Duluth, Department of Pharmacology/Department of Biochemistry & Molecular Biology and is Director of the Academic Health Center Duluth Women’s Mentoring Program. She has been a member of SOT and the Immunotoxicology Specialty Section since 1998. Dr. Regal received her Ph.D. in Pharmacology at the University of Minnesota in Minneapolis, Minnesota and did postdoctoral work in Immunology in the Department of Microbiology/Immunology, Albany Medical College, Albany, New York.

Dr. Regal’s current research is focused on respiratory allergy, especially asthma and she has authored over 50 research articles and reviews in peer-reviewed journals. Her research is focused on mechanistic studies of occupational asthma in animal models, as well as assessment of differences in asthmatic responses with age and gender. She is also a member of the American Association of Immunologists, American Thoracic Society and the American Society of Pharmacology and Experimental Therapeutics. She has served in all the officer positions in the Immunotoxicology Specialty Section as well as the Awards and Program committees for the Northland Chapter of SOT. In addition, in 2006 she participated in the exchange program between the Japanese Society of Immuntoxicology and the Immunotoxicology Specialty Section of SOT. She is currently Associate Editor of the Journal of Immunotoxicology and has served as a reviewer on multiple NIH panels, for the NTP Board of Scientific Counselors and for NIOSH. She participated as an immuntoxicologist on an Institute of Medicine Committee on Health Effects Associated with Exposures Experienced during the Persian Gulf War, in an ECVAM Expert Meeting regarding Progress in the development of New Approaches to the Identification of Respiratory Allergens in 2008, and has also participated in the ICCVAM Peer Panel for review of the Murine LLNA for assessing the allergic contact dermatitis potential of chemicals and products in 1997, 2008, and 2009.

In Vitro and Alternative Methods Specialty Section

David Allen, Ph.D., Past President

David Allen received his Ph.D. from North Carolina State University. He served as a Study Director and Senior Scientist for Pathology Associates, A Charles River Company before joining the US Food and Drug Administration Center for Drug Evaluation and Research as a Toxicologist. In this capacity, he was responsible for reviewing nonclinical pharmacology and toxicology studies submitted to the Division of Dermatological and Dental Drug Products in support of drug marketing applications. In addition, he served as an FDA representative on the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Dermal Corrosivity and Irritation Working Group. In 2004, he joined ILS, Inc. as a Toxicologist supporting the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). He currently serves as the Principal Investigator for the NICEATM support contract where he provides oversight of multiple ongoing evaluations of alternative toxicological test methods submitted for review/evaluation to NICEATM that reduce, refine, or replace the use of animals. Dr. Allen has published numerous articles and abstracts related to the research, development, and validation of alternative test methods in the areas of acute systemic toxicity, dermal and ocular corrosivity and irritation, endocrine disruptors, pyrogenicity, and skin sensitization.

In Vitro and Alternative Methods Specialty Section

Sharon Meyer, Ph.D., Past President

Dr. Meyer received her B.S. and M.S. from Iowa State and her Ph.D. from Cornell. She held postdoctoral positions at Harvard Medical School and Univ. North Carolina. She is currently Assoc. Professor in the Department of Toxicology, University of Louisiana-Monroe. She has published more than 40 papers on primary hepatocytes and enterocytes, neural and hepatoblastoma cell lines, and bone marrow stem cells. Her research is funded by DoD, and she has authored “Cellular Techniques in Toxicology” for Molecular and Biochemical Toxicology, 4th ed. Dr. Meyer has served as Vice President-Elect and Secretary/Treasurer for IVAM and as President of the South Central Regional Chapter, SOT. She believes an important priority for IVAM is facilitating education of toxicologists at all career stages to enable critical integration of multiple cellular/molecular responses to chemicals to understand organismal adverse responses. Through this service, it is anticipated that IVAM can impact on rational use of reductionist approaches to predict adverse human health effects.

Inhalation and Respiratory Specialty Section

Vincent Castranova, Ph.D., President

Vincent Castranova, Ph.D., is the Chief of the Pathology and Physiology Research Branch in the Health Effects Laboratory Division of the National Institute for Occupational Safety and Health, Morgantown, West Virginia. He holds the grade of a CDC Distinguished Consultant. He received the Shepard Lifetime Scientific Achievement Award from CDC in 2008 and the Stokinger Outstanding Achievement in Industrial Toxicology Award from ACGIH in 2009. He is also an adjunct professor in the Department of Basic Pharmaceutical Sciences at West Virginia University, Morgantown, West Virginia and the Department of Environmental and Occupational Medicine at the University of Pittsburgh.

Dr. Castranova received a B.S. in biology from Mount Saint Mary’s College, Emmitsburgh, Maryland in 1970, graduating magna cum laude. He received a Ph.D. in physiology and biophysics in 1974 from West Virginia University, Morgantown, West Virginia before becoming an NIH fellow and research faculty member in the Department of Physiology at Yale University, New Haven, Connecticut. In 1977, Dr. Castranova received a research staff position at the National Institute for Occupational Safety and Health and an adjunct faculty position at West Virginia University, Morgantown, West Virginia. He has served at these institutions since that time.

Dr. Castranova’s research interests have been concentrated in pulmonary toxicology and occupational lung disease. He has been coordinator of the Nanotoxicology Program in NIOSH since its inception in 2005. He has been a co-editor of four books and has co-authored over 470 manuscripts and book chapters.

Inhalation and Respiratory Specialty Section

Michael Kleinman, Ph.D., Vice President-Elect

Dr. Kleinman received his B.S. and M.S. in Chemistry in 1965 and 1971, respectively. He received his Ph.D. in Environmental Health Sciences from New York University in 1977. He is currently a Professor in the Department of Medicine at the University of California, Irvine, and Co-Director of the Air Pollution Health Effects Laboratory. Dr. Kleinman has published 100+ articles on toxicology of inhaled environmental contaminants. He served on two National Research Council committees on effects of chemical and biological weapons, and he currently chairs the California Air Quality Advisory Committee. He also serves on U.S. EPA Clean Air Scientific Advisory Committee (CASAC) panels. Dr. Kleinman has been a member of the Society of Toxicology’s Southern California Regional Chapter since 2002 and a member of the Inhalation and Respiratory Specialty Section since 2004.

Mechanisms Specialty Section

José E. Manautou, Ph.D., DABT, Vice President

Dr. José E. Manautou is Associate Professor of Toxicology and the Marlene L. Cohen and Jerome H. Fleisch Scholar in the Department of Pharmaceutical Sciences at the School of Pharmacy of the University of Connecticut. His research emphasizes mechanisms of toxicant action/interaction. His laboratory studies the role of multidrug resistance proteins in the hepatobiliary disposition of toxicants and the changes in expression of transport proteins in response to chemical liver injury. His group also investigates the biochemical and genetic determinants associated with the hepatoprotective actions of peroxisome proliferators and other chemicals that prevent drug liver injury. He has published numerous seminal articles on these research areas in both toxicology and liver-related journals. Dr. Manautou has been an active member of the Society of Toxicology (SOT) since he joined as a student member. In 2003, he was elected Councilor of the SOT and has also served in key committees and task forces for the society. Dr. Manautou was the recipient of the 2006 SOT Achievement Award and the 2008 AstraZeneca Traveling Lectureship Award. Dr. Manautou has served as member of the National Research Council Committee Assessing the Human Health Risks of Trichloroethylene and is currently Associate Editor for the journal Toxicology and Applied Pharmacology. He is also on the editorial board of four other journals. He served as member of the National Institutes of Health Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section and as external reviewer of grants for the European Commission. Dr. Manautou was recently appointed the NIH College of CSR Reviewers and was just nominated to be a member of the NIEHS Board of Scientific Counselors. Dr. Manautou received his B.S. in Pharmacy from the University of Puerto Rico, Ph.D. in Pharmacology and Toxicology from Purdue University and postdoctoral training in biochemical toxicology at the University of Connecticut. He also conducted sabbatical research at the Amsterdam Liver Center of the University of Amsterdam, The Netherlands.

Medical Device Specialty Section

Richard W. Hutchinson, D.V.M., Ph.D., DABT, Vice President

Dr. Richard W. Hutchinson received his B.S. from the University of Puget Sound in 1992. He received both a D.V.M. and a Ph.D. in Veterinary Anatomy from Texas A&M University in 1996 and 1998 respectively. He joined Johnson & Johnson (Ethicon) in 1998, and is currently a Research Fellow in the Preclinical Sciences Department. He is a diplomat of the American Board of Toxicology, and has been a member of the Society of Toxicology since 1999. He is chairman of the International Standards Organization (ISO) Subcommittee on Tissue product safety (ISO TC194/SC1).

Metals Specialty Section

Aaron Barchowsky, Ph.D., President

Dr. Barchowsky received his B.S. in Zoology from North Carolina State University in 1978 and a Ph.D. in Pharmacology from Duke University in 1984. He was a postdoctoral fellow in the Toxicology Training Program at Duke from 1985–1988 and held faculty positions in Clinical Pharmacology at Thomas Jefferson Medical School (1988–1991), the Department of Pharmacology and Toxicology at Dartmouth (1991–2003), and joined the Department of Environmental and Occupational Health at the University of Pittsburgh in 2003. He is active in graduate toxicology education and directs the Environmental Health Sciences Ph.D. program. He served on a number of national scientific review panels, including ALTX1, SIEE, XNDA, and VCMB. He also served as a consultant to the U.S. EPA on arsenic in drinking water and the Institute of Medicine on chromium supplements. He has been a Society member since 2001. He chairs the Education Committee, is the President of the Metals Specialty Section, and is an active member of both the Mechanisms and Cardiovascular Toxicology Specialty Sections. He is Vice President of the Allegheny-Erie Regional Chapter. He has maintained an NIH-funded research program investigating cellular signaling mechanisms of oxidants and the molecular pathogenesis of metals-induced vascular and pulmonary diseases.

Metals Specialty Section

J. Christopher States, Ph.D., Vice President

Dr. States received his B.S (Biochemistry) from State University of New York at Buffalo in 1974 and a Ph.D. (Pathology & Molecular Biology) from Albany Medical College, Union University in 1980. He was a post-doctoral fellow in the Department of Medical Biochemistry at University of Calgary (1980–1984). He is currently Professor, Distinguished University Scholar and Director of Graduate Admissions in Pharmacology & Toxicology, and Deputy Director of Center for Environmental Genetics and Integratives Biology at the University of Louisville School of Medicine. He served on multiple NIH grant review panels including Superfund, MBRS and ALTX-1 and XNDA Study Sections. He joined SOT in 1997 and is a member of Metals (Secretary/Treasurer, 2005–2007; VP-Elect, 2009), Molecular Biology, Reproductive and Developmental, and Cardiovascular Specialty Sections and Ohio Valley Chapter (Councilor, 2006–2010). His research interests include molecular biology and molecular genetics of arsenic toxicology and DNA damage and repair in humans.

Metals Specialty Section

Wei Zheng, Ph.D., Past President

Dr. Zheng is a Professor of Toxicology and University Faculty Scholar at Purdue University. Dr. Zheng is a recognized scholar in the fields of metal-induced neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease and essential tremors. Dr. Zheng received his B.S. and M.S. from Zhejiang University and his Ph.D. from University of Arizona. He held a joint appointment as an Assistant Professor (1993–2000) and later Associate Professor (2000–2003) in School of Public Health and College of Physicians and Surgeons at Columbia University in New York City. He came to Purdue in 2003 and became a Full Professor in 2006. Since Sept 1, 2008, Dr. Zheng has assumed the leadership as the Head of the School of Health Sciences and Associate Dean of College of Pharmacy, Nursing and Health Sciences at Purdue University in West Lafayette, Indiana. He has published one book and 113 manuscripts on manganese, lead, and copper neurotoxicities.

Mixtures Specialty Section

Michael Dourson, Ph.D., DABT, ATS, Vice President

Dr. Dourson is the President of the non-profit group Toxicology Excellence for Risk Assessment (TERA). Prior to TERA, he worked for 15 years for Environmental Protection Agency, holding several leadership roles and winning 4 bronze medals for joint efforts on specific key projects. Dr. Dourson received the SOT 2003 Lehman Award and the International Society of Regulatory Toxicology and Pharmacology’s 2009 International Achievement award. Two of his publications have won paper of the year awards from the SOT’s Risk Assessment Specialty Section (RASS). He has been elected to multiple officer positions including President of the American Board of Toxicology, President of the SOT RASS, Vice President-Elect of the SOT Mixtures Specialty Section, and Secretary of the Society for Risk Analysis. He is a media resource specialist in risk assessment for the SOT, a member of the editorial board of two journals, and vice chair of the NSF International Health Advisory Board.

Mixtures Specialty Section

Kendall Wallace, Ph.D., DABT, ATS, Vice President-Elect

Dr. Wallace is Professor of Biochemistry & Molecular Biology, University of Minnesota Medical School and Director, University of Minnesota Toxicology Graduate Program. He is a Diplomate of the American Board of Toxicology (1992), a Fellow of the Academy of Toxicological Sciences (2005), Editor of Toxicology, and President of StrataTox LLC. Dr. Wallace received his Ph.D. in Physiology from Michigan State University (1979) and was a Postdoctoral Fellow at the University of Iowa Toxicology Center (1979–1981). He has served SOT as President (2005–2006), Chair of the Continuing Education Committee (1991–1993), Finance Committee (1994–1997), President of the Northland Regional Chapter (1998–2000), Council Secretary (1999–2002) and Nominating Committee (2009–2011). His professional service includes: President of the Board of Directors, American Board of Toxicology (2001–2002), Vice-Chair and Chair of the Board of Directors for the ILSI Health and Environmental Sciences Institute, Councilor for IUTOX (2003–2004), U.S. EPA FQPA Scientific Advisory Panel member(1999–2001), Chair of the U.S. FDA Expert Working Group on Preclinical Biomarkers of Drug-induced Cardiac Injury, and President of the Mitochondrial Research Society (2003–2005).

Molecular Biology Specialty Section

Chris Corton, Ph.D., Vice President-Elect

Dr. Corton is presently a Senior Research Biologist in the Systems Biology Branch in NHEERL at U.S. EPA. He received his Ph.D. from the University of Kansas Medical Center in 1985 followed by a postdoctoral fellowship in yeast molecular biology at Duke University. From 1989 to 2002, he was a staff scientist at CIIT. Dr. Corton has been a member of SOT and the Molecular Biology Specialty Section since 1992. He was a member and Chair of the Continuing Education Committee and is past Secretary/Treasurer of the Carcinogenesis Specialty Section. He is the recipient of the 2010 AstraZeneca Traveling Lectureship award. Dr. Corton is active in SOT and has organized and co-chaired many symposia, roundtables, and CE courses. He is presently on the editorial boards of 6 journals including Toxicological Sciences and has been a reviewer and chair on over 30 peer review committees for NIH/NIEHS grants. As Vice President-Elect of the Molecular Biology Specialty Section (MBSS), he hopes to increase the career and educational opportunities for MBSS members, especially students and postdoctoral fellows, by further developing the interactions between MBSS and other specialty section and special interest groups in SOT and related scientific societies.

Nanotoxicology Specialty Section

David B. Warheit, Ph.D., DABT, ATS, President

Dr. Warheit is a Research Fellow at DuPont Haskell Global Centers in Newark, DE. He received his B.A. from the University of Michigan and his Ph.D. from Wayne State University School of Medicine. He was awarded an NIH Postdoctoral Fellowship and a Parker Francis Pulmonary Fellowship, both of which he took to NIEHS to study mechanisms of asbestos-related lung disease. In 1984, he moved to DuPont Haskell Laboratory. He has attained Diplomate status from the Academy of Toxicological Sciences (2000) and the American Board of Toxicology (1988) and served on NIH study sections. He has participated in several working groups, including IARC and the National Academy of Sciences, as well as several journal editorial boards, including current Associate Editor for Inhalation Toxicology and Toxicological Sciences. He is a past president of the Inhalation and Respiratory Specialty Section and a current member of the SOT Program Committee.

Nanotoxicology Specialty Section

Annette Santamaria, Ph.D., M.P.H., DABT, Past President

Dr. Santamaria is a Senior Manager in the Health Sciences Practice of ENVIRON International Corporation in Houston, Texas. She is a board-certified toxicologist and has extensive experience evaluating the health risks associated with exposure to a variety of consumer products, pharmaceuticals, medical devices, food additives, personal care products, and industrial chemicals. She developed the Nanotoxicology Specialty Section and currently serves as the section’s president. Dr. Santamaria has written a book chapter with Dr. Christie Sayes entitled “Toxicological Studies with Nanomaterials” for the book, “Risk Governance of Nanotechnology”. She has critically reviewed literature on nanometals (e.g., TiO2, ZnO, Silver) to evaluate the toxicity and potential for dermal penetration of these nanoparticles. She has also reviewed literature to evaluate the association between exposure to manganese and neurotoxicity, and has prepared comments on a variety of draft risk assessments that were conducted to develop guidance and regulatory levels for ambient manganese levels.

Neurotoxicology Specialty Section

Stephen Lasley, Ph.D., President

Dr. Lasley received his Ph.D. from the University of Louisville in 1979, and was a postdoctoral fellow in Environmental Health at the University of Cincinnati College of Medicine from 1979–1982. He joined the Dept. of Cancer Biology and Pharmacology at the University of Illinois College of Medicine in 1986. He is Course Director of the Medical Pharmacology course, chairs the local IACUC, has served on numerous grant review panels for NIH/NIEHS, and is an Associate Editor for NeuroToxicology. An SOT member since 1986, he was Councilor for the Neurotoxicology Specialty Section (2004–2006), and during that time, Chair of the subcommittee to review nominations for the NTSS Distinguished Investigator Award. Dr. Lasley has served as Director of the SOT Placement Service (1996–1997) and Chair of the SOT Animals in Research Committee (2004–2005). His research interests concern the neurotoxicity resulting from chronic exposure to heavy metals and the effects on the processes of neurotransmission underlying synaptic plasticity.

Neurotoxicology Specialty Section

Pam Lein, Ph.D., President-Elect

Dr. Lein received an M.S. in Environmental Health from East Tennessee State University (1983) and a Ph.D. in Pharmacology and Toxicology from the University of Buffalo School of Medicine (1990). She was a postdoctoral fellow in the Department of Molecular Immunology at Roswell Park Cancer Institute from 1990–1992. In 1993, she joined the faculty of the Biology department at Canisius College, where she developed a successful undergraduate program in neuroscience. In 1999, she joined the Department of Environmental Health Sciences, Division of Toxicological Sciences at the Johns Hopkins Bloomberg School of Public Health and began developing an independent research program in developmental neurotoxicology. In 2003, Dr. Lein was recruited to the Center for Research on Occupational and Environmental Toxicology (CROET) at Oregon Health & Science University. In 2008, she became an Associate Professor in Neurotoxicology with tenure in the Department of Molecular Biosciences, School of Veterinary Medicine at UC Davis. Her teaching responsibilities include veterinary and graduate courses in neurochemistry, developmental neurobiology and neurotoxicology. Her service activities include standing membership in the National Institutes of Health Neurotoxicology and Alcoholism (NAL) and in the National Science Foundation (NSF) Review Panel Integrative Organismal Biology/Developmental Systems Cluster. She serves on the editorial board of Toxicology and Applied Pharmacology, Journal of Toxicology, Neurotoxicology, and Current Neurobiological Research. She has been an SOT member since 2000 and a Councilor in the Neurotoxicology Specialty Section from 2005–2007. Dr. Lein’s research focuses on cellular and molecular mechanisms of neurotoxicity with particular emphasis on mechanisms by which organophosphorus pesticides, polychlorinated biphenyls or inflammatory mediators interfere with neuronal connectivity and contribute to childhood diseases such as autism and asthma.

Neurotoxicology Specialty Section

Susan L. Schantz, Ph.D., Past President

Dr. Schantz is a Professor of Environmental Toxicology at the University of Illinois, where she directs both the Interdisciplinary Environmental Toxicology Program and the NIEHS-funded Toxicology Training Grant. She received her B.A. in Psychology and her Ph.D. in Environmental Toxicology from the University of Wisconsin-Madison. She later did postdoctoral research in the Psychology Department at Wayne State University. Dr. Schantz has an active research program funded by NIEHS, NIA, U.S. EPA, and ATSDR, which focuses on understanding the nervous system effects of several widespread environmental contaminants including PCBs, PBDEs, bisphenol A and phthalates, and includes epidemiological studies of exposed human populations as well as parallel laboratory studies in animal models. She is currently a member of the Science Advisory Board for the International Joint Commission and serves an associate editor for Environmental Health Perspectives. She has been active in the Society of Toxicology for over 20 years.

Reproductive and Developmental Toxicology Specialty Section

Alan M. Hoberman, Ph.D., DABT, Fellow ATS, President

Dr. Hoberman was trained in anatomy and embryology at the University of Virginia and in toxicology at the University of Arkansas and the National Center for Toxicological Research. He worked in the field of toxicology for over 34 years and specialized in reproductive and developmental toxicology for over 31 years. As a Diplomate of the American Board of Toxicology (1988), Dr. Hoberman has over 70 publications and 188 presentations of abstracts and lectures in the fields of reproductive and developmental toxicology, neurotoxicology, inhalation toxicology, photobiology and regulatory toxicology. His current research interests include the development of the immune response and the assessment of compounds in young animals. Dr. Hoberman’s level of expertise in all aspects of preclinical toxicology and chemical safety testing has proven invaluable in the overall approval process to bring new entities to market.

Reproductive and Developmental Toxicology Specialty Section

Edward W. Carney, Vice President

Ed Carney is Director of Predictive Toxicology and Senior Advisor for Developmental and Reproductive Toxicology at The Dow Chemical Company, where he has been employed since 1992. External service includes the National Toxicology Program’s Board of Scientific Counselors, VP-Elect of the Teratology Society, VP of SOT RDT Specialty Section, Board of Toxicology Forum, various ILSI-HESI project teams, and the OECD Extended One-Generation Reproductive Toxicity study guideline group. Ed is an adjunct professor at The University of Michigan and a lecturer at University of Surrey (UK). He has published 70 peer-reviewed papers to date, with a focus on vitro methods, mode of action and assessment of chemical mixtures. He holds a B.S. from Cornell University (1981), and graduate degrees in reproductive physiology from University of Wisconsin-Madison and Cornell University (Ph.D., 1990). His postdoctoral research was conducted at the Lunenfeld Research Institute in Toronto.

Reproductive and Developmental Toxicology Specialty Section

Barry McIntyre, Ph.D., DABT, Vice President-Elect

Dr. McIntyre earned his Ph.D. from Washington State University in 1997 in Pharmacology/Toxicology. He was a National Institute of Environmental Health Sciences National Research Service Award Postdoctoral Fellow at the Chemical Industry Institute of Toxicology (CIIT) from 1998 till 2001. In 2001, he joined the Reproductive and Developmental Toxicology group at the Schering-Plough Research Institute as a reproductive toxicologist. He was accorded increasing levels of responsibilities, ultimately managing the US reproductive and developmental toxicology group. While at Schering-Plough he also represented Drug Safety on drug development teams where he designed, coordinated, and implemented non-clinical drug safety programs to support the clinical development of novel therapeutics. In January 2010, he left the pharmaceutical industry and joined the Toxicology Branch of the National Toxicology Program as a staff toxicologist. Dr. McIntyre has served as an ad hoc member for NIEHS Program Project Grants, NIEHS Special Emphasis Panel of the NTP Reproductive and Developmental Toxicology Board of Scientific Councilors, and the NTP-CERHR Bisphenol A Expert Panel. He has been a member of the SOT since 1992, served as a councilor in the Reproductive and Developmental Toxicology Specialty Section and has been active in the specialty section. He is also a past member of the Middle Atlantic Reproduction and Teratology Association (Councilor).

Reproductive and Developmental Toxicology Specialty Section

Mark E. Hurtt, Ph.D., Past President

Dr. Hurtt is Head of Global Reproductive and Developmental Toxicology at Pfizer Global Research and Development, Groton Laboratory He completed his formal education at the University of Cincinnati College of Medicine. He completed a post-doctoral fellowship at the Chemical Industry Institute of Toxicology in Research Triangle Park, North Carolina. Following a brief stay at Warner-Lambert in Ann Arbor, Michigan, Dr. Hurtt joined the DuPont Company. He held various roles over his 11 years at Haskell Laboratory for Toxicology and Industrial Medicine in Newark, Delaware, prior to joining Pfizer. Currently, Dr. Hurtt has overall responsibility for developmental and reproductive toxicology testing and consulting offerings as well as an investigative laboratory.

Risk Assessment Specialty Section

Edward V. Ohanian, Ph.D., Past President

Dr. Ohanian is the Director of the Health and Ecological Criteria Division, Office of Water, United States Environmental Protection Agency (U.S. EPA), in Washington, D.C. The Division is responsible for conducting human and ecological risk assessments as required under both the Safe Drinking Water Act and Clean Water Act. Recently, he has been appointed the Chairman of the USEPA Risk Assessment Forum. He also serves as an Adjunct Associate Professor with the School of Public Health and Health Services at George Washington University Medical Center. As a Co-Founder and Co-Chairman of the Federal-State Toxicology and Risk Analysis Committee, he has been instrumental in fostering cooperation and consistency regarding improved risk assessment and management methodologies. Recently, he was the co-editor of the book entitled “Toxicokinetics and Risk Assessment.” His elected and appointed positions at SOT have included: Committee on Public Communications; Councilor, Epidemiology Specialty Section, and Risk Assessment Specialty Section; and President, Risk Assessment Specialty Section. Dr. Ohanian is the recipient of the 2010 Arnold J. Lehman Award for his contributions to risk assessment and regulations of contaminants.

Toxicologic and Exploratory Pathology Specialty Section

Glenn H. Cantor, D.V.M., Ph.D., DACVP, President

Dr. Cantor received his A.B. from Cornell University and D.V.M. from Michigan State University. After 5 years in private veterinary practice, he did a residency in anatomic pathology at University of Florida, attained American College of Veterinary Pathology certification in Anatomic Pathology, and received his Ph.D. from the Department of Veterinary Microbiology & Pathology at Washington State University. In 1994, he joined the faculty of the Department of Veterinary Microbiology & Pathology, Washington State University, where he was first an Assistant Professor and then Associate Professor with tenure. His research was on the molecular pathogenesis of bovine leukemia virus infection and its role in altering host B-lymphocyte signal transduction. He also served as a senior diagnostic pathologist in the Washington Animal Disease Diagnostic Laboratory, where he taught residents and veterinary students. In 2002, Dr. Cantor joined the Investigative Pathology unit at Pharmacia Corp., Kalamazoo, Michigan where he coordinated the genetically engineered mouse phenotyping program and did research on metabonomics. In 2003, Dr. Cantor joined the Discovery Toxicology group at Bristol-Myers Squibb Co., Princeton, New Jersey, and is presently a Veterinary Pathology Fellow. He leads the efforts of the metabolism, pharmacokinetics, pharmaceutics, analytic chemistry, biotranformation, and discovery toxicology groups for several drug discovery projects, and serves as toxicology representative and pathologist on a number of other drug projects, mainly in the areas of oncology and cardiovascular disease. He served as associate editor for Veterinary Pathology (2004–2007). He has been a member of the SOT since 2002, served as a councilor in the Toxicologic and Exploratory Pathology Specialty Section (TEPSS) from 2005 to 2007, and is currently the President of TEPSS.

Toxicologic and Exploratory Pathology Specialty Section

Doug Wolf, D.V.M., Ph.D., Vice President

Dr. Wolf received his D.V.M. from the University of Missouri in 1981. After 6 years in clinical practice, he completed his pathology residency and Ph.D. in Veterinary Pathology at Purdue University in 1991. Dr. Wolf was a staff scientist for 6 years at the Chemical Industry Institute of Toxicology (CIIT), studying chemical carcinogenesis. From 1997–2007, he was a principal investigator at the National Health and Environmental Effects Research Laboratory (NHEERL) of the U.S. EPA, where he continued his work in carcinogenesis and molecular pathology. Currently, he is an Assistant Laboratory Director for NHEERL. Dr. Wolf has authored or coauthored over 125 journal articles, book chapters, and technical reports and has presented his work at numerous scientific meetings. He is an adjunct faculty member at North Carolina State University; University of North Carolina; and the Virginia Polytechnic Institute. Dr. Wolf was elected a Fellow of the International Academy of Toxicologic Pathologists in 2004 and a Fellow of the Academy of Toxicological Sciences in 2007.

Toxicologic and Exploratory Pathology Specialty Section

Norman J. Barlow, D.V.M., Ph.D., M.B.A., M.L.D., DAVCP, DABT, Vice President-Elect

Dr. Barlow received his D.V.M. from Michigan State University in 1996, completed a residency in anatomic pathology at North Carolina State University (NCSU) in 1998, and attained American College of Veterinary Pathology certification in 1999. He earned his Ph.D. in Comparative Biomedical Sciences from NCSU and the CIIT Centers for Health Research in 2003. Dr. Barlow’s doctoral research focused on the morphogenesis of phthalate-induced malformations in the developing male reproductive tract. In 2007, he attained certification by the American Board of Toxicology, and recently completed a Masters of Business Administration and a Masters of Leadership Development at Pennsylvania State University. In 2003, Dr. Barlow joined Aventis Pharmaceuticals as a veterinary pathologist and has had the opportunity to work at various sites including Bridgewater, NJ, Alfortville, France, and Malvern, PA. He was the Acting Head of Pathology in the U.S. from 2008 to 2009 and is currently the U.S. Head of Preclinical Safety for sanofi-aventis. Dr. Barlow has been a member of the SOT since 1999, served as a Councilor for TEPSS from 2008–2010, and has been active on the selection committee for the Roger O. McClellan Student Award.

Toxicologic and Exploratory Pathology Specialty Section

Charles W. Qualls, Jr., D.V.M., Ph.D., DACVP, Past President

Dr. Qualls is Executive Director of Investigative Toxicology at Amgen where he leads a group of experts that focuses on issue resolution and predictive toxicology. Prior to coming to Amgen Dr. Qualls served in various positions at Glaxo Wellcome/GlaxoSmithKline including Pathologist, Project Director, and Head of Molecular and Ultrastructural Pathology. Dr. Qualls has spent the majority of his career in academia. While on faculty in the Department of Pathology in the College of Veterinary Medicine at Oklahoma State University from 1982 to 1999 he was major advisor to 8 Ph.D. students and was on 18 graduate committees. His research focused on echo toxicology with major funding from the U.S. Army, U.S. Air Force and U.S. Environmental Protection Agency.